PRAME peptide-HLA-A*24:02 complex

The **PRAME peptide-HLA-A*24:02 complex** is a molecular complex consisting of a peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma), bound in the groove of the major histocompatibility complex class I molecule HLA-A*24:02. PRAME is expressed at high levels in multiple malignancies (including leukemias and solid tumors), but is typically absent from most normal adult tissues except testes[4][5][6]. The PRAME peptide is processed intracellularly and presented on the surface of tumor cells by HLA-A*24:02, where it can be specifically recognized by T cell receptors or engineered antibodies. This complex serves as a therapeutic target in cancer immunotherapy, enabling the development of TCR-engineered T cells, TCR-mimic antibodies, and other modalities aimed at harnessing the immune system to eliminate PRAME-expressing tumor cells with specificity dictated both by tumor antigen expression and by HLA type[2][4][6].

Other names

PRAME/HLA-A*24:02 complexPRAME peptide-MHC class I complexPRAME-A24 complex

TCR or antibody binding to the PRAME-HLA-A*24:02 complex leads to T cell activation and lysis of PRAME-expressing tumor cells[2][6]. Engineered T cells (e.g., TCR-T) or TCR-mimic antibodies recognize PRAME peptide presented by HLA-A*24:02 on tumor cells, leading to immune-mediated tumor killing[2][6].